Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-01-19 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, a foreign issuer. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The content includes detailed clinical trial results (TOPAZ-1 Phase III trial) for the drug Imfinzi in biliary tract cancer, with extensive data on survival rates, progression-free survival, adverse events, and other clinical outcomes. The document is a regulatory filing reporting material clinical trial results and related corporate information, but it is not an annual report, earnings release, or other specific financial report. It is a periodic report of material information by a foreign issuer. Given the nature of Form 6-K filings and the detailed clinical and corporate update, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication announcement. Therefore, the best fit is Regulatory Filings (RNS) with high confidence.
2022-01-19 English
IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed clinical trial results and scientific data about the HIMALAYA Phase III trial for Imfinzi and tremelimumab in liver cancer. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing to disclose material information to the SEC and investors. The document length is about 15,000 characters, and it contains substantive content rather than just an announcement or certification. Form 6-K filings are generally classified under Regulatory Filings (RNS) as they are miscellaneous reports by foreign issuers that do not fit other categories such as 10-K or IR. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-01-19 English
Imfinzi improves survival in biliary tract cancer
Earnings Release Classification · 99% confidence The document begins with 'RNS Number : 8834Y' and includes the date '19 January 2022'. It details positive clinical trial results (TOPAZ-1 Phase III) for a drug (Imfinzi) and includes quotes from executives and detailed efficacy tables. The presence of the RNS header, the nature of the announcement (a significant clinical trial update), and the closing statement referencing RNS and the London Stock Exchange strongly indicate this is a regulatory news service announcement. Since this is a specific announcement of clinical trial data/results, it fits best under the general 'Regulatory Filings' category (RNS) as it is not a formal financial report (like 10-K or IR) or a specific management/governance filing. It is a general regulatory disclosure. Q3 2021
2022-01-19 English
Imfinzi combo shows unprecedented survival in HCC
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 8833Y' and is dated '19 January 2022'. It contains a headline announcing positive clinical trial results ('Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer') and includes detailed efficacy tables and scientific context. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a formal announcement of material news via the RNS system—indicates a regulatory filing that is not a full annual report (10-K), quarterly report (IR), or earnings release (ER) which typically focus on standardized financial statements. Since it is a general regulatory announcement disseminated through the official news service (RNS) and doesn't fit the specific categories like DIV, DIRS, or ER, the most appropriate classification is the general regulatory filing category.
2022-01-19 English
ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the FDA granting Priority Review for Enhertu, a breast cancer treatment, including clinical trial data, regulatory status, and drug development updates. The content is regulatory and informational about a specific event and drug approval process, not a financial report or earnings release. Form 6-K filings are typically regulatory filings for foreign issuers to report material information. The document does not contain financial statements or management discussion of financial results, nor is it an announcement of voting results or capital changes. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-01-18 English
Enhertu granted Priority Review for breast cancer
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement distributed via the London Stock Exchange's RNS service. The content details a specific regulatory event: the FDA granting Priority Review for the drug Enhertu for HER2-positive metastatic breast cancer, referencing clinical trial data (DESTINY-Breast03) and regulatory programs (RTOR, Project Orbis). This is a material corporate event announcement concerning regulatory progress, not a full financial report (like 10-K or IR) or a general shareholder communication (like DEF 14A). Since it is a specific regulatory update that doesn't fit perfectly into the financial report categories (10-K, IR, ER, MRQ), and it is clearly an official announcement distributed via RNS, the most appropriate classification is the general regulatory announcement category, RNS, as it is a primary information provider announcement.
2022-01-17 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.